Human adenovirus serotype 5 (HAdV-5) attaches to its primary receptor, the coxsackie and adenovirus receptor (CAR) as the first step of infection. However, CAR expression decreases as tumors progress, thereby diminishing the utility of HAdV-5-based vectors for cancer therapy. In contrast, many aggressive tumor cells highly express CD46, a cellular receptor for HAdV-3. We hypothesized that a mosaic HAdV vector, containing two kinds of fiber proteins, would provide extensive transduction in a heterogeneous population of tumor cells with varying expression levels of HAdV receptors. We therefore generated a fiber-mosaic HAdV vector displaying both a chimeric HAdV-3 fiber and the HAdV-5 fiber protein. We verified the structural integrity of purified viral particles and confirmed that the fiber-mosaic HAdV vector has expanded tropism. We conclude that the use of fiber-mosaic HAdV vectors is a promising approach for transducing a heterogeneous cell population with different expression levels of adenovirus receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.virol.2010.08.010DOI Listing

Publication Analysis

Top Keywords

hadv vector
12
fiber-mosaic hadv
12
human adenovirus
8
fiber proteins
8
heterogeneous cell
8
tumor cells
8
expression levels
8
hadv
5
adenoviral vector
4
vector expressing
4

Similar Publications

Article Synopsis
  • Human adenovirus type 5 (HAdV-5)-based oncolytic viruses have potential for cancer therapy, but face challenges like poor targeting and liver toxicity.
  • Researchers created a modified HAdV-5 vector (HAdV-5-HexPos3_ΔCAR) that improves cancer cell targeting and reduces off-target effects, especially in liver tissues.
  • The modified vector showed a significant increase in tumor presence while minimizing adverse effects, suggesting it could enhance the efficacy and safety of adenoviral cancer treatments.
View Article and Find Full Text PDF

Adenovirus (AdV) infection has been rarely documented in cats and other felids. Partial sequences of the hexon and fiber genes of a Hungarian feline adenovirus isolate (FeAdV isolate) showed a close relationship to human AdV (HAdV) type C1. Further molecular and biological characterization is reported here.

View Article and Find Full Text PDF

Adenoviruses are important human pathogens that are widespread and mainly associated with respiratory and gastrointestinal infections. In a previous study on human adenovirus (HAdV) seroprevalence, we observed reduced binding antibody levels against a range of HAdV types in sera collected from students in 2021 compared to sera collected before the SARS-CoV-2 pandemic. In this follow-up study, we wanted to verify this observation in a cohort of regular blood donors for whom serial samples were available.

View Article and Find Full Text PDF

Human adenovirus (HAdV)-based oncolytic vectors, which are designed to preferentially replicate in and kill cancer cells, have shown modest efficacy in human clinical trials in part due to poor viral distribution throughout the tumor mass. Previously, we showed that expression of the p14 fusion-associated small transmembrane (FAST) fusogenic protein could enhance oncolytic HAdV efficacy and reduce tumor growth rate in a human xenograft mouse model of cancer. We now explore whether co-expression of the adenovirus death protein (ADP) with p14 FAST protein could synergize to further enhance oncolytic vector efficacy.

View Article and Find Full Text PDF
Article Synopsis
  • The human adenovirus (HAdV) is rapidly spreading among children in India, with around 12,000 cases reported in 2022, posing a significant public health threat due to the lack of vaccines or preventative policies.
  • Key strategies to combat HAdV outbreaks include early detection, isolation, and the implementation of effective treatment protocols, such as using antiviral drugs and cleaning surfaces.
  • Ongoing research into antibody interactions and existing vaccines hints at potential future therapeutic options to better manage and control HAdV infections.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!